Exemestane and chemotherapy as first-line treatment of metastatic breast cancer: results of a phase II study. (Record no. 20043059)

MARC details
000 -LEADER
fixed length control field 01698 a2200445 4500
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20250515234631.0
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 201011s 0 0 eng d
022 ## - INTERNATIONAL STANDARD SERIAL NUMBER
International Standard Serial Number 1938-0666
024 7# - OTHER STANDARD IDENTIFIER
Standard number or code 10.3816/CBC.2010.n.041
Source of number or code doi
040 ## - CATALOGING SOURCE
Original cataloging agency NLM
Language of cataloging eng
Transcribing agency NLM
100 1# - MAIN ENTRY--PERSONAL NAME
Personal name de la Haba-Rodriguez, Juan
264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE
Date of production, publication, distribution, manufacture, or copyright notice 20101122
245 00 - TITLE STATEMENT
Title Exemestane and chemotherapy as first-line treatment of metastatic breast cancer: results of a phase II study.
Medium [electronic resource]
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Name of publisher, distributor, etc. Clinical breast cancer
Date of publication, distribution, etc. Aug 2010
300 ## - PHYSICAL DESCRIPTION
Extent 313-7 p.
Other physical details digital
500 ## - GENERAL NOTE
General note Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Aged
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Androstadienes
General subdivision therapeutic use
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Antineoplastic Combined Chemotherapy Protocols
General subdivision therapeutic use
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Aromatase Inhibitors
General subdivision therapeutic use
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Breast Neoplasms
General subdivision drug therapy
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Cyclophosphamide
General subdivision administration & dosage
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Disease-Free Survival
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Epirubicin
General subdivision administration & dosage
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Female
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Fluorouracil
General subdivision administration & dosage
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Humans
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Kaplan-Meier Estimate
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Middle Aged
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Postmenopause
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Treatment Outcome
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Mancha, Rosario González
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Manga, Gumersindo Pérez
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Aguilar, Enrique Aranda
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Baena Cañada, José Manuel
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Rovira, Pedro Sánchez
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Conejo, Emilio Alba
773 0# - HOST ITEM ENTRY
Title Clinical breast cancer
Related parts vol. 10
-- no. 4
-- p. 313-7
856 40 - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier <a href="https://doi.org/10.3816/CBC.2010.n.041">https://doi.org/10.3816/CBC.2010.n.041</a>
Public note Available from publisher's website

No items available.